APB-102

N/A

Report date: 2023/10/26 20:01:00

Base Information

Drug NameAPB-102
Drug Alias Namerecombinant AAVrh10 vector expressed anti-SOD1 microRNAAPB-102AMT-162
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAVrh10 vector
Mechanisms of ActionSuperoxide dismutase inhibitorsGuanine nucleotide exchange C9orf72 modulatorsGene silencing +[4] 
TargetsSuperoxide dismutaseGuanine nucleotide exchange C9orf72
Therapy Area/IndicationsAmyotrophic Lateral Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSweden
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Massachusetts Medical School
China Registration ClassN/A

Develop Information

Active CompaniesUniqureApic BioUniqure Biopharma Bv
Inactive CompaniesN/A
Active IndicationsAmyotrophic Lateral Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A